Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The pattern of relapse, treatment and final outcome of 235 patients with osteosarcoma of the extremity who relapsed after neoadjuvant treatments performed between 1986 and 1998 at a single institution is reported. The 235 relapses were treated by surgery, surgery plus second line chemotherapy, and only second line chemotherapy or radiotherapy. The 5-year post-relapse-event-free-survival (PREFS) was 27.6% and the post-relapse-overall-survival (PROS) 28.7%. All 69 patients who are presently alive and free of disease were treated by surgery, alone or combined with chemotherapy. None of patients treated only by chemotherapy or radiotherapy survived. We conclude that it is possible to obtain prolonged survival and cure in about 1/4 of relapsing osteosarcoma patients with aggressive treatments. The complete removal of the recurrence is essential for outcome, while the role of the association of second-line chemotherapy remains to be defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These results suggest that surgical resection was associated with prolonged survival, consistent with published data.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“The prognosis for patients with recurrent osteosarcoma is poor [1–4].”
From Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial (2021) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Bacci, G., Ferrari, S., Bertoni, F., Ruggieri, P., Picci, P., Longhi, A., Casadei, R., Fabbri, N., Forni, C., Versari, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4016 · Cited by 438
Self-citationGoorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.165 · Cited by 395
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Bacci, G., Picci, P., Ferrari, S., Ruggieri, P., Casadei, R., Tienghi, A., Prever, A. B. D., Gherlinzoni, F., Mercuri, M., & Monti, C. (1993) · Cancer · doi:10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c · Cited by 294
Self-citationPicci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., Bertoni, F., Guerra, A., Capanna, R., Albisinni, U., et al. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7<1515::aid-cncr2820560707>3.0.co;2-6 · Cited by 274
Self-citationBacci, G., Picci, P., Ruggieri, P., Mercuri, M., Avella, M., Capanna, R., Brach Del Prever, A., Mancini, A., Gherlinzoni, F., Padovani, G., et al. (1990) · Cancer · doi:10.1002/1097-0142(19900601)65:11<2539::aid-cncr2820651125>3.0.co;2-m · Cited by 235
Self-citationSystemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival
Sæter, G., Høie, J., Stenwig, A. E., Johansson, A., Hannisdal, E., & Solheim, Ø. P. (1995) · Cancer · doi:10.1002/1097-0142(19950301)75:5<1084::aid-cncr2820750506>3.0.co;2-f · Cited by 190
Neoadjuvant chemotherapy for osteosarcoma of the extremity
Bacci, G., Briccoli, A., Ferrari, S., Longhi, A., Mercuri, M., Capanna, R., Donati, D., Lari, S., Forni, C., & DePaolis, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00229-5 · Cited by 174
Self-citationScandinavian Sarcoma Group Osteosarcoma Study SSG VIII
Smeland, S., Müller, C., Alvegard, T. A., Wiklund, T., Wiebe, T., Björk, O., Stenwig, A. E., Willén, H., Holmström, T., Follerås, G., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00747-5 · Cited by 166
Research works printed but not linked: 2
- Martini N, 1971, J Bone Joint Surg (Am), 12, 271
- Heij HA, 1994, Surgery, 115, 687
Cited by
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Chou, A. J., & Gorlick, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1075 · Cited by 377
Bielack, S. S., Kempf-Bielack, B., Branscheid, D., Carrle, D., Friedel, G., Helmke, K., Kevric, M., Jundt, G., Kühne, T., Maas, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2305 · Cited by 238
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 234
Metadata
- Authors
- Bacci, G., Briccoli, A., Longhi, A., Ferrari, S., Mercuri, M., Faggioli, F., Versari, M., & Picci, P.
- Affiliations
- Istituto Ortopedico Rizzoli (IT)
- Ospedale Sant'Anna (IT)
- Corresponding author
- Bacci, Gaetano
- Venue
- Acta Oncologica
- Published
- 2005-01
- Volume
- 44
- Issue
- 7
- Pages
- 748-755
- ISSN
- 0284-186X (ISSN-L)
- 1651-226X
- OpenAlex
- W2104688502
- Cited by
- 134
- References
- 27
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 11 · 2022: 5 · 2021: 5 · 2020: 9 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 9 · 2015: 12 · 2014: 8 · 2013: 7 · 2012: 7
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Acta Oncologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- recurrent osteosarcoma, neoadjuvant chemotherapy, limb-sparing surgery, second-line chemotherapy, radiotherapy, extremity osteosarcoma
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Female, Humans, Male, Neoplasm Recurrence, Local, Prognosis, Osteosarcoma, Salvage Therapy, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. https://app.cochat.ai/papers/10.1080/02841860500327503
- The paper
- Bacci, G., Briccoli, A., Longhi, A., Ferrari, S., Mercuri, M., Faggioli, F., Versari, M., & Picci, P. (2005). Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncologica. https://doi.org/10.1080/02841860500327503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.